The Valley Desk

NCT03260322 · Interventional trial

A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Overall registry status Completed

Phase 1

Conditions Advanced Solid Tumors

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov